• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Trodelvy Falls Short As NSCLC Treatment, Taking Some of the Shine Off Antibody-Drug Conjugates


Gilead's share price fell 10% today after it announced that Trodelvy, an antibody-drug conjugate, failed to meet its overall survival end point in a trial testing it as treatment for metatstatic non-small cell lung cancer.

Antibody-drug conjugates have been a hot ticket in oncology lately. Johnson & Johnson announced earlier this month that it had purchased Ambrx, a California company developing the antibody-drug conjugates, for $2 billion. Merck announced in October 2023 that had signed a deal worth up to $22 billion with Daiichi Sankyo to commercialize three antibody-conjugate. Earlier in the year, Pfizer announced that it was shelling out $43 billion to buy Seagen, a Washington state company developing antibody-drug conjugates.

Some bloom came off the category today when Gilead announced that its antibody-drug conjugate, Trodelvy (sactituzumab-govitecan) had failed to meet its primary endpoint in a phase 3 testing the drug as a treatment for metastatic non-small cell lung cancer.

Gilead’s (Nasdaq: GILD) stock price fell 10% today following the early morning announcement.

Antibody-drug conjugates are combination drugs that consist of a monoclonal antibody that “finds” the cancer and a drug that kills the cancer cell. Hitching the cytoxic agent to the monoclonal antibody makes the killing action of the cytoxic agent more precise.

Trodelvy (pronounced troh-DELL-vee) has been on the market as a treatment for other cancers for several years. The FDA approved it on an accelerated basis in 2020 for triple-negative breast cancer, a relatively rare and aggressive form of breast cancer. In 2021, the drug regulator approved it as a treatment for bladder cancer. In February 2023, the FDA approved Trodelvy for previously treated HR-positive, HER2-negative breast cancer. HR-positive, HER2-negative breast cancer is among the most common types of breast cancer, so that approval has been characterized in media reports as crucial to the drug’s commercial success.

The findings announced in today’s news release were from the EVOKE-01 trial, a phase 3 trial comparing treatment with Trodelvy to docetaxel, a taxane that is used to treat several types of cancer. Gilead said in the release that a three-month difference in median overall survival was seen in a subgroup of patients who were nonresponsive to the last prior anti-PD-(L)1 therapy, a class of drugs that includes Tecentriq (atezolizumab) and Imfinzi (durvalumab) but that subgroup analysis was not designed for formal statistical testing.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.